Results 131 to 140 of about 99,629 (284)

Psychedelics, entactogens and psychoplastogens for depression and related disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Increased Hippocampal AMPA and NMDA Receptor Subunit Immunoreactivity in Temporal Lobe Epilepsy Patients [PDF]

open access: bronze, 1998
Gary W. Mathern   +9 more
openalex   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

open access: yesBritish Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller   +3 more
wiley   +1 more source

Distinct impacts of sodium channel blockers on the strength–duration properties of human motor cortex neurons

open access: yesEpilepsia, EarlyView.
Abstract Objective This study was undertaken to determine how voltage‐gated sodium channel (VGSC) blockers modulate cortical excitability in vivo. VGSCs are critical for regulating axonal excitability, yet the effects of sodium channel‐blocking medications on human cortical neurons remain poorly characterized.
Lorenzo Rocchi   +6 more
wiley   +1 more source

WONOEP XVII appraisal: Targeting network excitability beyond the synapse ‐Neurotransmitter, ionic, and electro ‐diffusions

open access: yesEpilepsia, EarlyView.
Abstract Epilepsy affects approximately 1% of the population worldwide, and although medications are effective in the majority of cases, seizures persist in approximately 30% of patients. Despite the effort to develop new antiseizure drugs, the rate of pharmacoresistance in patients has not diminished over the past 3 decades. There is thus a real unmet
Vincent Magloire   +9 more
wiley   +1 more source

Electrical stimulation of stem cell–derived human neural networks for evaluating anti‐seizure medications

open access: yesEpilepsia, EarlyView.
Abstract Objective Current preclinical epilepsy drug screening relies on animal models that poorly reflect human neurophysiology, leading to high failure rates in clinical translation. We aimed to establish a human in vitro model using human‐induced pluripotent stem cell (hiPSC)–derived cortical neurons cultured on multielectrode arrays (MEAs), capable
Joshua Nicholls   +13 more
wiley   +1 more source

Stimulation of Dopamine D4 Receptors in the Nucleus Accumbens Shell Increases Palatable Food Intake in Satiated Male Rats: Modulation by NMDA and AMPA Receptors

open access: yesBrain Sciences
Background/Objectives: Palatability significantly influences food consumption, often leading to overeating and obesity by activating the brain’s reward systems.
Refugio Cruz-Trujillo   +7 more
doaj   +1 more source

Topiramate for the treatment of neonatal seizures and beyond

open access: yesEpilepsia, EarlyView.
Abstract Acute symptomatic neonatal seizures are one of the most common neurological disorders in newborns admitted to neonatal intensive care units and require prompt treatment. Up to 50% of neonatal seizures are refractory to first‐line medications such as phenobarbital (PB), and another 30% fail second‐line therapy.
Wolfgang Löscher, Janet S. Soul
wiley   +1 more source

The discovery of YM900 and its pharmacological characterization as a selective and potent α-amino-3-hydroxy-5-methylisoxazole-4-propionate(AMPA) receptor antagonist.

open access: gold, 1993
Masao Shimizu‐Sasamata   +6 more
openalex   +1 more source

Home - About - Disclaimer - Privacy